�Թϲ�����

Insurers are scrambling to blunt the expense of new drugs that can carry prices of more than $2 million per treatment, offering new setups aimed at making the cost of gene therapies more manageable for employers. Cigna Corp. announced Thursday a new program that allows employers and insurers to pay per-month fees for a service that will cover the cost of gene therapies and manage their use. CVS Health Corp. says it plans to offer a new layer of coverage specifically for gene therapies, which would handle employers’ costs above a certain threshold. (Walker and Wilde Mathews, 9/5)

In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a "Lazarus effect" in some patients because it can reverse late-stage cancer that has defied all other treatment options. Developed by Eli Lilly and Co's Loxo Oncology and marketed by German drugmaker Bayer, it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. (9/6)

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type. Novartis aims to file for U.S. approval for oral capmatinib later this year as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), the Basel-based company said on Friday. (9/6)